Is Current Price Of Stryker Stock A Strong Support? Trefis Team Tue, November 10, 2026 at 11:48 AM EST 4 min read SYK -1.03% ^GSPC -0.77% MDT -1.08% JNJ -0.04% ZBH -0.25% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
For questions about this article or underlying research, email help@trefis.com.
If you own Stryker (SYK), the past year has been hard: the stock lost 6.9% over the past twelve months, including dividends, while the S&P 500 returned 13.7%. The shares now trade at $325.73, close to a price where they bounced in 2024. So has this price held lately? Not since 2024: each time the stock has come back to it since November 2024, it went on to fall 5%.
How Stryker Stock Fared At This Price Before
Stryker stock mounted two strong rallies from this level in 2024, but subsequent returns to this price have broken downward. Following a May 2024 close of $324.30, shares climbed as much as 23.3% over the following twelve months. The stock closed at $319.60 that August and subsequently rose as much as 26.3%.
Since November 5, 2024, Stryker stock has dropped back to this price four times, and each time it fell 5% without first rising 20%. The latest of those visits came on July 31, 2026, at $325.70, and by September 3, the stock had closed at $307.99. It fell further later in September, then returned 17.5%, including dividends, over the past month to reach today's price. Its September 24 close of $268.90 sat below both support levels in the table.
What A Bounce Could Be Worth To You
An initial $10,000 investment at today's price would grow to about $12,040 if the stock climbed back to resistance, where its past rallies stalled. A typical 2024 bounce from this level would have pushed the same purchase to about $12,480, placing current resistance slightly below what those bounces delivered. Neither figure represents a base case, as both prior bounces occurred in 2024, before the recent downward reversals. During any upward move, the shares would also pass two levels below resistance where previous rallies stalled, at $350.20 and $372.32.
Stryker's profits offer one reason a bounce remains plausible. Stryker recorded an operating margin of 21.8% over the twelve months to September 30, 2026, excluding a $293 million goodwill impairment, its highest level at any quarter end since late 2016. MedSurg and Neurotechnology, the larger of the company's two segments, posted 9.1% organic sales growth in the third quarter, and management said the order book remains strong and elevated.
Sales are growing more slowly than Stryker's recent pace, though. Revenue rose 7.9% over the twelve months to September 30, 2026, against an average of 9.8% across the twelve-month periods to September 2024, 2025 and 2026.
What Could Break Stryker's Support
A slowing hip and knee business is the clearest threat, and management has already cut its outlook partly because of it. On October 29, management lowered the 2026 organic sales growth forecast to a range of 6.5% to 7%, citing softer hip and knee procedure trends alongside lingering supply constraints in peripheral vascular. Management also cited execution risk on capital equipment sales. The revised guidance carries a 6.8% midpoint.
Management estimated hip and knee market growth at about 2.5% in 2026 and said Stryker has not been winning at its historical rate. Third-quarter U.S. knee sales grew 1.3% organically, while U.S. hip sales fell 0.6%, against strong prior-year comparisons. If the stock breaks support, the next support level sits at $293.30, 10.0% under today's price.
Management expects fourth-quarter organic growth similar to the 7.7% organic growth it reported for the third quarter. When Stryker issues its next earnings report, expected in January 2027, the number to watch will be whether fourth-quarter organic sales growth matches the third quarter's 7.7%, as management expects, and whether U.S. knee and hip sales improve.
Not Sure Stryker Is Worth It At This Price?
You don't have to bet on one stock to earn. The Trefis Income Solution owns 50 companies chosen to keep paying dividends, each with at least 10 straight years of dividends, yielding about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.
